Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

India’s Expanding Vaccines Market Offers Promise To Global And Local Drug Firms (Part 2 of 2)

This article was originally published in PharmAsia News

Executive Summary

Several drug companies are gearing up to go full throttle into the Indian vaccines market with programs that go beyond pushing products and seek to build up public health awareness on a larger scale. GSK, Sanofi, Merck, Novartis and Pfizer are in the fray with local players Serum Institute of India, Bharat Biotech, and Panacea Biotec.

You may also be interested in...



Pressure For Bexsero: Fate Of Novartis Vaccines Unit Hangs On Success

The EU CHMP’s recommendation in favor of Novartis’ Meningitis B vaccine Bexsero is a positive turn for the company’s vaccines business, but with the division’s sales and profits languishing, some investors are wondering if Novartis should cut its losses and get out of the space.

WHO Delists Panacea Biotec's Combination Vaccines From Pre-qualified List; Move Comes A Year After Action Against Sanofi's Shantha Unit

MUMBAI - In a stern signal intended to ensure product quality, the World Health Organization delisted combination vaccines made by Indian vaccine maker Panacea Biotec Ltd. from its list of pre-qualified suppliers

Is Sanofi Planning High-Level Changes At India's Vaccines Unit Shantha? A Leading Biocon Scientist Joins Shantha

MUMBAI - Two years after it bagged Indian vaccines specialist Shantha Biotechnics Ltd. with an aim to develop low-cost vaccines, Sanofi is set to rollout significant changes in the management of its acquired Hyderabad site in Central India

Topics

Related Companies

UsernamePublicRestriction

Register

SC084501

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel